Is CV Sciences efficiently growing its dividend?
CV Sciences does not have a long track record of dividend growth. In the past three months, CV Sciences insiders have not sold or bought any company stock. Only 6.80% of the stock of CV Sciences is held by insiders. Only 0.02% of the stock of CV Sciences is held by institutions.
Should you hold CV Sciences (cvsi) stock?
The consensus among Wall Street equities research analysts is that investors should "hold" CV Sciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CVSI, but not buy additional shares or sell existing shares. View analyst ratings for CV Sciences or view top-rated stocks.
What are Wall Street's price targets for CV Sciences'stock?
3 Wall Street analysts have issued 12 month price objectives for CV Sciences' shares. Their predictions range from $5.00 to $9.00. On average, they anticipate CV Sciences' stock price to reach $7.33 in the next year.
How far is CV Sciences from its 52-week low?
According to the current price, CV Sciences is 125.16% away from the 52-week low. What was the 52-week high for CV Sciences stock? The high in the last 52 weeks of CV Sciences stock was 0.48. According to the current price, CV Sciences is 10.00% away from the 52-week high.
Should I buy CV Sciences stock?
Should I buy or sell CV Sciences stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CV Sciences in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" CV Sciences stock.
What does CV Sciences do?
We provide research based solutions for the well being of the planet. This is health transformed.
Is CV Sciences CBD good?
CV Sciences made it stand out by making sure the company delivers high-quality products to the masses always. As of September 2018, CV Sciences obtained the GRAS (Generally Recognized as Safe by FDA standards) designation on its CBD products.
Why is CV Sciences stock dropping?
The reported decline in sales for 2021, which dropped from $24.4 million in 2020 to $20.0 million last year, were chalked up to increased market competition, which is largely due to the uncertain regulatory environment for CBD, said the company.
Should I buy or sell CV Sciences stock right now?
2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CV Sciences in the last year. There are currently 2 hold ratings...
What is CV Sciences' stock price forecast for 2022?
2 brokerages have issued 1-year price targets for CV Sciences' stock. Their CVSI stock forecasts range from $0.17 to $0.17. On average, they antici...
How has CV Sciences' stock performed in 2022?
CV Sciences' stock was trading at $0.12 at the start of the year. Since then, CVSI shares have decreased by 62.5% and is now trading at $0.0450. V...
How were CV Sciences' earnings last quarter?
CV Sciences, Inc. (OTCMKTS:CVSI) issued its quarterly earnings results on Monday, May, 16th. The company reported ($0.02) EPS for the quarter, meet...
Who are CV Sciences' key executives?
CV Sciences' management team includes the following people: Mr. Joseph D. Dowling , CEO, Sec. & Director (Age 65, Pay $418.52k) Mr. Joerg Grasse...
Who are some of CV Sciences' key competitors?
Some companies that are related to CV Sciences include RegeneRx Biopharmaceuticals (RGRX) , Lotus Pharmaceuticals (LTUS) , Emerald Bioscience (E...
What other stocks do shareholders of CV Sciences own?
Based on aggregate information from My MarketBeat watchlists, some companies that other CV Sciences investors own include (CGC) , Aurora Cannabi...
What is CV Sciences' stock symbol?
CV Sciences trades on the OTCMKTS under the ticker symbol "CVSI."
How do I buy shares of CV Sciences?
Shares of CVSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBul...
Is CV Sciences stock a Buy, Sell or Hold?
CV Sciences stock has received a consensus rating of hold. The average rating score is and is based on 0 buy ratings, 4 hold ratings, and 0 sell ra...
What was the 52-week low for CV Sciences stock?
The low in the last 52 weeks of CV Sciences stock was 0.04. According to the current price, CV Sciences is 117.34% away from the 52-week low.
What was the 52-week high for CV Sciences stock?
The high in the last 52 weeks of CV Sciences stock was 0.48. According to the current price, CV Sciences is 9.38% away from the 52-week high.
What are analysts forecasts for CV Sciences stock?
The 4 analysts offering price forecasts for CV Sciences have a median target of 0.48, with a high estimate of 0.65 and a low estimate of 0.17. The...
About CV Sciences
Headlines
CV Sciences, Inc. engages in the development, manufacture, and sale of consumer and pharmaceutical products. It operates through the Consumer Products and Specialty Pharmaceutical segments. The Consumer Products segment includes manufacturing, marketing, and selling of hemp-based cannabidiol products through the PlusCBD brand.
CV Sciences (OTCMKTS:CVSI) Frequently Asked Questions
Is Medical Marijuana Really A Slippery Slope? CVSI Distribution Agreement with GNC
What is CV Sciences?
3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CV Sciences in the last twelve months. There are currently 3 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CV Sciences stock.
Where is CV Sciences located?
CV Sciences, Inc. operates as a life science company in the United States. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The Consumer Products segment develops, manufactures, and markets plant-based dietary supplements and hemp-based cannabidiol (CBD) products under the PlusCBD name in various market sectors, including nutraceutical, beauty care, and specialty foods. It serves internet sales, direct-to-consumer health and wellness stores, collectives, cooperatives, master distributors, specialty retailers, and convenience stores, as well as food, drug, and mass merchandise retailers. The Specialty Pharmaceutical segment focuses on developing and commercializing cannabinoids to treat medical indications. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.
Is Medical Marijuana Really A Slippery Slope? CVSI Distribution Agreement with GNC
and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California. More... Sector.
The Week In Cannabis: Stocks Down, Republican Legalization Bill, Germany, Uruguay, Earnings, New ETF And More
The Best Daily Overview Of The Cannabis Space CV Sciences Announces New Distribution Agreement with GNC. $CVSI Massachusetts cannabis prices continue to fall Kentucky GOP Sen. Damon Thayer: "Medical cannabis is a slippery slope for recreational marijuana.”
